Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.1K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.1K
Multiple Comparison Tests01:13

Multiple Comparison Tests

4.0K
Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
4.0K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

350
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
350
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

670
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
670
Sign Test for Matched Pairs01:17

Sign Test for Matched Pairs

229
The sign test for matched pairs offers a robust method for comparing two paired samples, often for the effects of an intervention in one of them. This method is very useful in situations where the underlying distribution of the data is unknown. The test compares two related samples—often pre- and post-treatment measurements on the same subjects—to determine if there are significant differences in their median values.
To conduct the sign test, we first calculate the differences in...
229
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

13
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
13

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reference intervals reimagined with IRIS for earlier detection and better disease monitoring.

Scientific reports·2026
Same author

Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls.

Communications medicine·2026
Same author

Standardized digital PCR assay validation using PCR-ValiPal, demonstrated in cross-platform quantification of bovine papilloma virus.

Analytica chimica acta·2026
Same author

The impact of Symprove™ multi-strain probiotic on enterotoxigenic Escherichia coli- or antibiotic-induced gut microbiome dysbiosis using high-throughput in vitro screening.

Food research international (Ottawa, Ont.)·2026
Same author

Removal of unwanted variation in pseudobulk analysis of single-cell RNA sequencing data and the leveraging of pseudoreplicates.

NAR genomics and bioinformatics·2025
Same author

Assessing differential cell composition in single-cell studies using voomCLR.

Bioinformatics (Oxford, England)·2025

Related Experiment Video

Updated: Oct 18, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.9K

Statistical detection of synergy: New methods and a comparative study.

Olivier Thas1,2,3, Annelies Tourny4, Bie Verbist5

  • 1Data Science Institute, I-Biostat, Hasselt University, Hasselt, Belgium.

Pharmaceutical Statistics
|October 5, 2021
PubMed
Summary

This study enhances the BIGL R-package for drug combination screening, improving synergy analysis by accounting for non-constant variance and offering new null models. The updated package provides reliable bootstrap confidence intervals for synergy strength.

Keywords:
simulation studystatistical testssynergy

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.1K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.7K

Related Experiment Videos

Last Updated: Oct 18, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.9K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.1K
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.7K

Area of Science:

  • Pharmacology
  • Biostatistics
  • Drug Discovery

Background:

  • Combination therapies are crucial for improving treatment efficacy and managing drug resistance.
  • Synergistic drug combinations are identified early in drug discovery by comparing observed effects to null models.
  • The BIGL R-package facilitates rapid screening of drug combinations.

Purpose of the Study:

  • To extend existing synergy testing methods in the BIGL R-package.
  • To incorporate non-constant response variance and a wider range of null models (Loewe, Loewe2, HSA, Bliss).
  • To introduce bootstrap confidence intervals for enhanced synergy assessment.

Main Methods:

  • Development and evaluation of extended meanR and maxR tests within the BIGL R-package.
  • Comprehensive simulation studies under diverse additivity/synergy models, dose-response scenarios, and variance assumptions.
  • Implementation of bootstrap confidence intervals for synergy strength and off-axis points.

Main Results:

  • The extended BIGL tests demonstrate robust performance across various simulation conditions.
  • Bootstrap confidence intervals exhibit reliable coverage, complementing existing synergy tests.
  • Differences in null model performance were minimal and scenario-dependent, emphasizing expert knowledge for selection.

Conclusions:

  • The enhanced BIGL R-package offers a more versatile and reliable tool for drug synergy screening.
  • The choice of null model in synergy analysis should be guided by specific biological context and expert judgment.
  • The updated package and its features are demonstrated on a real-world drug discovery dataset.